

Recommendations from York and Scarborough Medicines Commissioning Committee September 2015

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Alprostadil 3 mg/g cream (Vitaros®)	Erectile dysfunction	Approved	As per CCG referral support service guidance.	Approved for use after full trial of PDE-5 inhibitors failed or are contraindicated in line with CCG RSS guidance	Green	Less costly than other alprostadil products for erectile dysfunction.
Vitamin B compound strong tablets	Re-feeding syndrome	Approved	<a href="#">NICE CG 32</a> and local gastroenterology clinician opinions.	Uses supported by NICE CG and local clinicians indicate some patients require use beyond the initial 10 day period.	Amber – specialist initiation	Limited – savings expected from decommissioning for alcohol detoxification.
Naloxegol (Moventig®)	Opioid induced constipation	Approved	Approved in accordance with <a href="#">NICE TA 345</a> .	For those who have not responded to at least 2 full dose laxatives and dietary advice.	Green	Limited use in palliative care.
Vedolizumab (Entyvio®)	Crohn's Disease	Approved	Approved in accordance with <a href="#">NICE TA 352</a> .	Where anti TNF therapy has failed/contraindicated.	Red	Local figures to be confirmed.
Edoxaban (Lixiana®)	Treatment / prevention of recurrent DVT and PE	Approved	Approved in accordance with <a href="#">NICE TA 354</a> .	Is an option for treating DVT/PE alongside the other commissioned NOAC's and warfarin.	Green	Unlikely to have any significant cost impact as would displace other commissioned options.

Fumaric acid esters (Fumaderm®) unlicensed	Plaque psoriasis	Approved	Confirmation of current position.	Stated as plaque psoriasis unresponsive to conventional therapy (topical agents, phototherapy) or where contraindicated.	Red	No cost to CCG.
Toujeo® 300 units/ml (insulin glargine) pre-filled pen	Diabetes mellitus	Approved	Provides high dose insulin at less cost than insulin degludec.	For patients on insulin glargine (Lantus®) who require: <ul style="list-style-type: none"> <li>• High dose (60+ units) per dose</li> <li>• Large volume of insulin + local site reactions</li> <li>• Twice daily insulin</li> </ul> <p>NOTE: Toujeo 300mg/mL is not bioequivalent to insulin glargine 100mg/mL.</p>	Green	No significant cost pressure expected. Costs less than Tresiba® (insulin glargine).
Tresiba®▼ (Insulin degludec)	Diabetes mellitus	Approved	Toujeo® is the 1 <sup>st</sup> choice high strength insulin. Insulin degludec would be an option after Toujeo®.	For use in patients for whom insulin U500 would otherwise be prescribed and for patients with significant nocturnal hypoglycaemia.	Amber – specialist initiation	Toujeo® 300 units/ml costs less than Tresiba® (insulin glargine).
Prucalopride 1mg/2mg (Resolor®)	Chronic constipation in men	Approved	Clinical evidence does not support use in men.	Not routinely commissioned	Black	No cost impact.

**Other items to approve:**

- CCG RSS guidance on erectile dysfunction
- Fosfomycin leaflet – update on licensed indication